practice, the infrarenal aorta is considered aneurysmal if the diameter is ≥30 mm (reF.
3 ), but this definition might not be appropriate for women, who have smaller diameter arteries than men 4 , and for individuals with arteriomegaly, a condition of generalized arterial dilata tion. When reporting a dilatation of the diameter of the infrarenal aorta in a patient, the diameter of the undila ted adjacent aorta should be taken into consideration, although this is not always feasible in clinical practice 5 . Thus, AAA should be diagnosed when the ratio of the diameters of the infrarenal and undilated suprarenal aorta is ≥1.5. On the basis of the diameter of the aorta, AAA can be classified as small (not considered for repair, <55 mm) or large (≥55 mm), when surgical repair can be considered 6 . Aneurysms result from progressive changes in the arterial wall in response to multifactorial causes; the resultant changes in wall structure and arterial pres sure lead to thinning of the wall, with the degradation of extracellular matrix (ECM) in the adventitia and loss of vascular smooth muscle cells (VSMCs) in the media increasing the susceptibility to rupture 7 . Theoretically, if an AAA is left untreated, its diameter increases grad ually; large AAAs are at increased risk of rupture. AAA ruptures can occur intraperitoneally, retroperitoneally or, rarely, in other organs such as the duodenum or the inferior vena cava. Rupture usually leads to sudden onset abdominal or back pain and haemorrhagic shock.
Abdominal aortic aneurysms
Natzi Sakalihasan 1, 2 *, Jean-Baptiste Michel 3 , Athanasios Katsargyris 4 , Helena Kuivaniemi 5 , Jean-Olivier Defraigne 1, 2 The severity of shock varies with the location and extent of the rupture. This condition, if left untreated, results in almost 100% mortality 6 . In very rare cases, AAA rupture causes a small loss of blood in the retroperitoneal space, where it can become contained, causing pain but no haemodynamic instability. As most patients with intact AAA are asymptomatic, AAA is commonly an undiag nosed condition. Incidental or systematic screening of at risk groups is the most effective approach to prevent AAA related death. Because of the high mortality asso ciated with AAA rupture, most patients diagnosed with large AAAs are offered either open repair surgery (to support the aneurysmal infrarenal aorta with inlay tube shaped or bifurcated prosthetic vascular grafts sewn into the aorta) or endovascular aortic repair (EVAR), where a stent graft is introduced and placed inside the aneu rysm via the iliac arteries. The success of EVAR depends on the morphology of the aorta and associated arteries; EVAR can be accomplished safely in those >80 years of age 8 . This Primer provides a contemporary overview of the pathogenesis, diagnosis, treatment and outcome of patients with AAA, focusing on fusiform AAA.
Epidemiology

Disease burden
Incidence and prevalence. Globally and in developed countries, the prevalence and incidence of AAA have decreased during the past two decades, but in some areas, such as Latin America and highincome Asian-Pacific countries, the prevalence is possibly increasing 9 . The prevalence also varies worldwide between ethnic groups and between sexes 9 . Of note, overall, there is a lack of solid knowledge on the true prevalence of AAA world wide, as reports on the prevalence of AAA detected via ultrasonography screening programmes in women and men are available from only a few countries (see below). Most reports show regional variations in treatment rates, which might reflect a selection bias, as access to afford able health care varies greatly in different populations. Finally, temporal variations in prevalence trends might actually reflect changes in sociodemographics in some countries. The variations in prevalence for men in devel oped countries are best observed in population based screening programmes [10] [11] [12] . The most recent ultrasonography based screening studies diagnose AAA in 1-2% of all 65year old men and in 0.5% of 70year old women [9] [10] [11] [12] . However, some persons are diagnosed outside of these programmes, are treated before 65 years of age or are non participants, and all these situations would slightly increase the true prevalence in the general population 10, 12 . In Denmark, the AAA prevalence is slightly higher, at 2.6% in 65year old men and 0.9% in 71year old women 13 . A recent population based report from Sweden includ ing untreated and treated women and men showed a slight increase in individuals diagnosed with intact AAA over time (from 46 per 100,000 people of >45 years of age in 2001 to 51 per 100,000 people in 2015, with a peak at 73 per 100,000 people in 2011) 14 . This increase is likely due to the introduction of screening in men rather than a true general increase in the incidence of AAA in the population. The decline in cases of ruptured AAA from 22 per 100,000 people to 12 per 100,000 people during the same time period could confirm this assertion 14 . There has been a decline in the number of male smokers, which could contribute to the decline in both the AAA prevalence and rupture 15 .
Morbidity and mortality. During the past decade, AAA related death has been the 12-15th leading cause of death in persons of >55 years of age in the United States, the United Kingdom and several European coun tries, as reported by the Centers for Disease Control and Prevention's Web based Injury Statistics Query and Reporting System (CDC WISQARS; see Related links), the UK Office for National Statistics (UK Office for National Statistics; see Related links) and the Swedish National Board of Health and Welfare (Swedish National Board of Health and Welfare; see Related links). The overall mortality in patients with AAA is high, in both treated and untreated patient groups, when compared with the general population, best shown by the excess in observed mortality (standardized mortality rate (SMR) 1.71 for patients with AAA who have been treated), mainly owing to the high co occurrence of atheroscle rotic disease, mostly cardiovascular disease 13, 16, 17 . Besides cardiovascular causes of death, cancer is a common cause of death in patients with AAA 11, [16] [17] [18] . The true inci dence of deaths associated with ruptured AAA outside of health care institutions is difficult to determine given the decline in autopsy rates, but 50% of patients with ruptured AAA have been reported to die before they can be admitted to hospital 19 . Although women are under represented in most AAA studies, their outcomes are often reported to be worse than those in men, including a higher rupture risk of small aneurysms and more complicated aneu rysm morphology, which makes the AAA more difficult to treat with standard surgical care [20] [21] [22] . Women with AAA also seem to have a worse prognosis than men. A 2017 meta analysis comparing the outcomes of AAA repair (EVAR and open repair surgery) between men and women showed that 30day mortality was higher in women than in men both for EVAR (2.3% and 1.4%, respectively, OR 1.67, 95% CI 1.38-2.04) and open repair surgery (5.4% and 2.8%, respectively, OR 1.76, 95% CI 1.35-2.30) 22 . Women were also less likely to be mor phologically eligible for EVAR and were less frequently offered prophylactic repair than men. The authors suggested that a smaller threshold for intervention for women improves outcomes, as women have smaller aor tas than men 4 . However, the benefit of such a measure could be hindered by the fact that women are reported to have smaller general vascular dimensions and more challenging morphology, both of which can complicate all elective repair procedures.
Differences in outcomes following AAA repair between different ethnicities have also been demon strated, with specific ethnic groups having worse short term and mid term prognoses than others. Maori patients in New Zealand had inferior mid term survival after EVAR and open repair surgery compared with all other ethnic groups in New Zealand 23 . Analysis of data from the Vascular Quality Initiative demonstrated that black patients in the United States have a higher risk of developing postoperative renal failure and returning to the operating room than white and Asian patients 24 .
Asian patients were more likely to experience post operative myocardial infarction than African American and white patients 24 . Other studies have shown that Hispanic individuals in the United States have higher perioperative morbidity rates and mortality following both EVAR and open repair surgery than other ethnic groups 25, 26 . Different factors have been suggested to explain these differences in outcomes between ethnicities.
These factors include different access to high quality health care centres (for example, Afro Caribbean patients are treated more often than other ethnic groups in low volume centres); differences in the anatomical extent of the AAA (for example, Afro Caribbean and Asian patients seem to have concomitant iliac artery aneurysms requiring more complex procedures more often than patients in other ethnic groups); and differ ences in preoperative comorbidities (for example, black patients have a higher incidence of hypertension than non black patients).
Risk factors
The common fusiform AAA is a complex, multifactor ial disease with both genetic and environmental risk factors that usually manifests at late age. The abdomi nal infrarenal aorta is a common site for atherosclerotic non aneurysmal occlusive disease, and AAA is often associated with atherosclerosis. AAAs and occlusive atherothrombotic disease share several risk factors, including smoking, older age, a positive family history and male sex 6, 12, [27] [28] [29] . However, current evidence based on molecular stud ies has demonstrated that atherosclerosis and AAA are distinct disease entities 30 . Several at risk groups have a very high prevalence of AAA, such as smokers, persons with a family history of AAA and patients with coro nary heart disease, hyperlipidaemia, hypertension and chronic obstructive pulmonary disease (COPD) 15, 18, 31, 32 . The prevalence of AAA among individuals with diabe tes mellitus is lower than in the general population, in contrast to the prevalence in individuals with occlusive . b | Morphological classification of aneurysms; inset shows details of the normal aortic wall. Regardless of the imaging method, the dilatation of the aorta should be measured in both anterior-posterior and transverse directions. Measurement could be based on inner-to-inner, leading edge-to-leading edge or outer-to-outer boundaries; outer-to-outer boundary measurements indicate the maximal diameter. Part a adapted from reF.
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, Springer Nature Limited. atherothrombotic disease 33 . The AAA growth rate is also slower in patients with diabetes mellitus. The possibility that metformin, a commonly used drug used to manage type 2 diabetes mellitus, inhibits AAA growth has been addressed in several recent reports 34, 35 . The lower prevalence and later development of dis ease in women may be partly explained by sexhormone related protection, equivalent to that observed in other manifestations of cardiovascular disease 20 . The possible protective effects of exogenous or endogenous female sex hormones (such as oestrogen) on AAA develop ment have been investigated in some registry based and questionnaire based studies, showing conflicting results 20 . It is highly probable that smoking is a more detrimental risk factor in women than in men, perhaps modulated by the effect of smoking on reproductive func tion in women, such as premature menopause, and the negative effects on lipid levels, lowering high density lipoprotein (HDL) and increasing triglycerides 15, 20, 36, 37 .
Genetic risk factors for AAA. Aortic aneurysms can be found in patients with rare genetic diseases, such as Ehlers-Danlos syndrome type IV (also known as the vascular type), Marfan syndrome, Loeys-Dietz syn drome and fibromuscular dysplasia 38 . Most patients with AAAs do not, however, have any of these rare genetic diseases. Approximately 10-20% of patients with AAA have at least one relative with this condition 29, 39 , and formal segregation analyses indicate that genetic mod els explain this familial aggregation 40, 41 . On the basis of two large twin studies from Sweden 42 and Denmark 43 , the phenotypic variance determined by genetics is esti mated to be 70-80%, whereas non shared environmen tal effects (such as smoking, infections or occupational exposure) contribute to the remaining 20-30%. Having a first degree relative with an AAA is a significant risk factor (OR 1.96, 95% CI 1.68-2.28) for the person to develop an AAA 28 . A positive family history for AAA has been suggested to have clinical implications, as familial AAA cases are reported to have increased growth rate 44 or higher rupture risk 29 than sporadic cases and possibly also worse outcomes after EVAR 45, 46 . Family based genetic studies 47 are difficult to carry out for AAA because it typically manifests at an advanced age and is often a deadly disease; these factors limit the number of patients available for such studies. AAA is also usually asymptomatic, and ultrasonography screening is required to detect AAA in family members. Genetic association studies using cases and controls have become the preferred method to identify genetic risk factors for AAA 48 . The largest genome wide associ ation study (GWAS) for AAA included 4,972 AAA cases and 99,858 controls in the discovery phase, followed by genotyping in independent validation cohorts with 5,232 AAA cases and 7,908 controls 49 . The combined analyses with the discovery and validation data sets iden tified nine AAA risk loci (Table 1) , five of which were previously known and four of which were new loci.
Despite their highly significant associations with AAA (Table 1) , these nine genetic loci explain only a small proportion of the heritability of AAA. Furthermore, the biology underlying these genetic associations still needs to be defined. One study used VSMCs isolated from patients with AAA and controls to assess DNA methyl ation in the genes found within the nine associated loci 50 . Altered DNA methylation levels were found in three genes (vets avian erythroblastosis virus E26 oncogene homologue (ERG), IL6 receptor (IL6R) and SET and MYND domaincontaining 2 (SMYD2)), suggesting that epigenetic mechanisms such as DNA methylation are implicated in AAA development. The proteins ERG and SMYD2 are transcriptional regulators controlling The table summarizes the genome-wide significant (P < 5 × 10
) and validated associations. CDKN2BAS1, CDKN2B antisense RNA 1, also known as ANRIL; CELSR2, cadherin EGF LAG seven-pass G-type receptor 2; DAB2IP, DAB2 interacting protein; ERG, v-ets avian erythroblastosis virus E26 oncogene homologue; IL6R, IL-6 receptor; LDLR, low-density lipoprotein receptor; LINC00540, long intergenic non-protein coding RNA 540; MAF, minor allele frequency (a measure of how common the variant is in the population); MMP9, matrix metalloproteinase 9; PCIF1, PDX1 (pancreatic and duodenal homeobox 1) C-terminal inhibiting factor 1; PSRC1, proline and serine rich coiled-coil 1; SMYD2, SET and MYND domain-containing 2 (SET domain-containing proteins, such as SMYD2, catalyse lysine methylation); SNP, single nucleotide polymorphism; SORT1, sortilin 1; ZNF335, zinc-finger protein 335. Data from reF. Finally, AAAs seem to differ genetically from thor acic aortic aneurysms and dissections, and these con ditions do not usually co occur in the same family 53 . The overlap between the genetic loci currently known to be associated with thoracic aortic aneurysms and dis sections and those associated with AAA is limited 54, 55 , suggesting that the pathobiology in the two aneurys mal diseases is distinct. For example, none of the nine AAA loci have been associated with thoracic aortic aneurysms and dissections, but interestingly, one of them (rs10757274) has been associated with intracranial aneurysms 56 . It is also worth noting that the embryolog ical origin of VSMCs in the abdominal aorta is splanch nic mesoderm, whereas VSMCs in the thoracic region originate from neural crest 54 . VSMCs with different embryo logical origins respond differently to biolog ical stimuli such as cytokines and growth factors. The best studied example is the response to transforming growth factor β (TGFβ). TGFβ treatment of neural crest VSMCs demonstrated increased DNA synthesis and collagen production, whereas mesodermal VSMCs did not respond 57 .
Growth and rupture risk of AAA
In the literature and in clinical practice, the continuous enlargement of an AAA due to a degenerative weaken ing of the wall is called 'growth' of the AAA. The mean growth rate is 2.5 mm per year in AAAs (39-49 mm in diameter) and is 20-25% faster in current smokers and 25% slower in patients with diabetes mellitus, possibly due to metformin treatment or to alterations in ECM turnover 34, 58, 59 . A minority of patients diagnosed with AAA do not have a detectable enlargement of their AAA 60 . The majority of aneurysms enlarge over time in a nonlinear mode, and the measurement methodology influences the accuracy. Other factors that have been inconsistently reported to be associated with increased growth are hypertension, female sex and COPD 34, 60, 61 . Individuals with an undiagnosed AAA who are not under surveillance are at risk of AAA rupture, which can lead to sudden death from massive intra abdominal bleeding. Thus, patients diagnosed with AAA should be surveyed. The most commonly reported factor influenc ing the risk of rupture is the size of the aneurysm. Size is, therefore, the basis for all surveillance protocols of patients with AAA 6, 62 ; however, contemporary reports show that other factors (such as AAA morphology) influencing the risk could also be considered. The accu racy of predicting the risk of AAA rupture on the basis of AAA diameter holds some weaknesses because in a few patients, the AAA will rupture at <55 mm diameter even under surveillance at a vascular clinic 34 . One of the larger meta analyses in the field confirmed the higher rupture risk in women than in men and an increased risk in current smokers and those with untreated hyper tension 20, 34, 61 . Thus, precision medicine options to iden tify more patient specific rupture risk predictors are under investigation, using factors such as aneurysm volume, aortic size index (the association between aortic width and body surface area), family history of AAA, presence of diabetes mellitus and biomarkers, such as circulating matrix metalloproteinases (MMPs) or microRNAs 22, [63] [64] [65] [66] [67] [68] [69] . The increased rupture risk reported for women could be associated with the relatively larger aortic size compared with the expected aortic diam eter; thus, the aortic size index could be a future tool to consider for optimized individualized surveillance of women 69 . Some registry based reports suggest that the use of fluoroquinolones causes collagen breakdown in the aortic wall, which could increase the risk of hos pital care or death from aortic disease (thoracic aortic aneurysms, dissection or AAA) 70 . The reported rupture risk, which varies as a function of diameter, has been derived from studies of patients with AAA who did not receive preventive repair surgery owing to the presence of comorbidities 62 . However, the 2018 North American guidelines indicate that the rupture risk, based on diameter alone, may be lower than previ ously reported 62 . Previously reported annual rupture risks for patients with AAAs were negligible for AAA <40 mm, 0.7-1.0 per 100 person years for AAA 40-54 mm, 9 per 100 person years for AAA 55-59 mm, 10 per 100 person years for AAA 60-69 mm and 33 per 100 person years for AAA >70 mm (reFs 62, 71 ). A contemporary pooled analysis indicates that the annual rupture risk would be 5.3 per 100 person years for AAA 55-70 mm and 6.3 per 100 person years for AAA >70 mm; this reduction might be associated with the declining number of current smokers among patients with AAA. Women with small AAAs seem to have a higher rupture risk than men 60, 61 .
Mechanisms/pathophysiology
Our knowledge of AAA pathobiology is mostly based on histological and molecular evaluation of tissue sam ples of the abdominal aorta removed during open repair surgery, mostly of large AAAs, compared with aortas with occlusive disease and healthy aortas, although ani mal models are available (box 1). AAA is characterized by proteolytic fragmentation of the ECM, VSMC death, immune cell infiltration of the adventitia and increased oxidative stress in the aortic wall. Molecular studies using high throughput microarray based genome wide analyses have demonstrated that AAAs are character ized by a more important adaptive immune response than occlusive atherothrombotic aortic disease 30 . Aneurysms are characterized by a more important medial injury than intimal atheroma, mainly caused by proteolysis and oxidative processes 72 . The ECM, with its main fibrillar insoluble components, elastin and collagen, supports the haemodynamic load of the aortic wall. The action of proteases that progressively degrade the ECM is considered the most influential mechanism for the development and progression of AAAs (Fig. 2 ).
Atherothrombosis and haemodynamics
Although AAA is a different disease entity from occlu sive atherothrombotic diseases, these two conditions share common initial pathophysiological mechanisms. In occlusive atherothrombotic diseases, the disruption to the blood flow caused by atherosclerotic lesions (also called atherosclerotic plaques or atheroma, that is, subendothelial accumulations of fat (lipids including low density lipoprotein (LDL)) is compounded by the formation of a superimposed intraluminal thrombus (ILT), a blood clot.
Atheroma begins with an outward convection of plasma lipoproteins, mainly LDL, through the wall. These initial fatty streaks evolve towards the forma tion of a plaque, and luminal intraparietal haemor rhage can lead to the formation of intraplaque and/or luminal clots, forming the pathological substrate for both occlusive atherothrombotic disease and AAA 73 . Atherothrombotic diseases are specific to arteries, with atheroma localizing preferentially to specific sites, including those proximal to branching and bifurcations, such as the infrarenal aorta.
The propensity of the infrarenal aorta for dilatation associated with atherothrombotic disease is due to spe cific haemodynamic conditions associated with the iliac bifurcation; these conditions promote pressure reflective waves, owing to the impact of blood flow on a bifurca tion. Pressure reflective waves within the blood trans form kinetic energy into potential energy. This physical phenomenon increases the outward radial transporta tion of plasma molecules and microparticles 74 through the wall and collisions of circulating cells between one another and the aortic wall (Fig. 2) . A study in the 1980s showed that AAA was more frequent in men with above knee amputation, and a greater curvature of the aorta developed on the opposite side of the non amputated leg 75 , suggesting that reflection waves on the remaining limb bifurcation play an important part in the develop ment and lateralization of AAAs. Haemodynamics also contributes to the understanding of the different risks of ILT at low blood pressure (embolic risk) or high blood pressure (arterial wall degradation and rupture risk, embolic risk not completely excluded). In the aorta, where the blood pressure is high, radial convection (out ward mass transport through the wall generated by the pressure gradient between the luminal blood pressure (100 mmHg) and the interstitial pressure in the adventi tia (10 mmHg)) pushes the ILT components within the wall, which may contribute to progressive dilatation and risk of rupture 76 . In particular, changes in haemodynam ics within the ILT (bleeding within the ILT, the socalled attenuating crescent sign) may indicate urgent appraisal for intervention 77 . Thus, despite the ability of the ILT to limit biomechanical wall stress owing to the increased full thickness of the wall 78 , the outward convection of proteolytic and oxidative activities from the ILT to the wall outweighs its biomechanical protective advantage.
The role of the intraluminal thrombus during the development of AAAs. The structure of AAAs is composed of, starting from the aorta lumen, a multilayered ILT (in the majority of cases); a thin, degraded media, with few VSMCs and elastic components; and an inflammatory and/or fibrotic adventitia, which can be thicker than nor mal owing to inflammation and oedema. However, the ILTs associated with AAAs have different features than the ILTs that form in occlusive atherothrombotic disease (see below). Permanently renewed by circulating blood, the ILT is a highly proteolytic and oxidative environ ment, and no cells (endothelial cells, SMCs or mesen chymal progenitors) can spread and pro liferate in close contact with the ILT. Thus, owing to the presence of the ILT, there is neither endothelium nor intima in AAAs.
The role of the ILT is linked to its biological activities, which are continuously renewed at the luminal inter face with blood. In AAAs, the ILT is a spatiotemporally dynamic neo tissue that is able to degrade the underlying aortic wall through one mechanism. First, the ILT tem porally recruits fibrinogen, circulating cellular elements such as polymorphonuclear (PMN) leukocytes, includ ing neutrophils, platelets 79 and red blood cells (RBCs) 80 , and macromolecules such as HDL 81 , and it could thereby deplete these elements from the circulation. Second, the enzymes and other components released by the cells that aggregate at the ILT and by fibrin (plasmin), spatially convected outwardly through the wall, contribute to ECM degradation and the adventitial immune response. Of note, ILT development is also enhanced by trapped bacteria (see below).
Rarely, patients with AAAs also develop (as a con sequence of ILT activities) consumptive coagulopathy. These patients have increased risk of systemic bleeding, owing to decreased platelet counts and plasma fibrino gen levels and associated increases in plasma D dimers (a product of fibrin degradation) 82 . D dimers are the hallmark of fibrinolysis and plasmin activation, which have a major role in proteolytic injury of the wall. The usual physiological healing response to this injury may include the recruitment of stromal cells, VSMCs and cir culating mesenchymal cell progenitors to the damaged tissue. However, the consumption of RBCs, neutrophils Box 1 | animal models of aaa a recent review summarized numerous publications on the experimental animal models of abdominal aortic aneurysm (aaa) 184 . in animal models, only pharmacological approaches that both degrade the arterial wall and maintain intraluminal thrombus (iLt) biological activity would perpetuate the aortic injury 212 , thereby enhancing the dilatation and possible subsequent rupture 97 . in this context, bacterial contamination of the iLt by weak pathogens, such as Porphyromonas gingivalis, mainly from dental and periodontal origin, in animals as well as in humans, may promote the progression of aaas 97 via neutrophil recruitment and activation 213 . One of the common features of experimental animal models is that the progression of the dilatation stops with the cessation of the initial stimulus (elastase, angiotensin ii or calcium chloride), initiating a process of healing by mesenchymal cells (mainly vascular smooth muscle cells (vsMCs)). this observation could suggest that, in human disease, the stimuli do not cease, as aaas progressively enlarge. it also supports the staccato evolution of aaa in humans, in which latent (healing) phases are present between evolutionary phases (stimuli) 214 . However, such comparisons between human and experimental models are confounded by three important stimuli not found in most animal models: smoking, ageing and hypertension.
and fibrinogen by the ILT could hamper such cellular responses 83 . These biological activities are not dependent on the ILT volume but on its age: the fresher the ILT, the more biologically active it is, particularly at the edges.
Extracellular matrix
The blood containing function of the arterial wall mainly depends on the ECM, whose components are synthesized by SMCs and processed by VSMCs. Lysyl oxidase, synthesized and secreted by VSMCs, is the main enzyme involved in the maturation of fibrillar struc tures (elastin and collagen), possibly rendering them inso luble. The ECM is constituted of macrofibrillar and microfibrillar structures of crosslinked proteins (macro: elastin and collagen; micro: fibronectin, fibril lin, and so on). In this context, elastin is reputed to resist dilatation and collagen to resist rupture 84 .
The degradation of the ECM is largely due to out wardly convected proteases 85 . Because of pressure gradi ent between the circulating blood (≥80-120 mmHg in older persons) and the interstitial pressure in the adven titia (10 mmHg), proteases released by neutrophils, or directly plasma borne zymogens, are outwardly con vected through the wall, provoking ECM degradation and progressive dilatation.
Elastin damage was preferentially associated with progressive dilatation, whereas collagen damage led to rupture 84 . Two protease families are predominantly linked to AAA progression: serine proteases, which degrade the ECM directly or indirectly, by degrading adhesive proteins (such as fibronectin and fibrillin) that are more sensitive to proteolysis than the macro molecular components, and activated MMPs 67 , which can directly degrade the ECM (Fig. 2) . Of note, these , and activate the pro-matrix metalloproteinases (MMPs; the inactive precursors of MMPs). Plasminogen is activated into plasmin on ILT fibrin by tissue-type or urokinase-type plasminogen activator (t-PA or u-PA, respectively, both serine proteases). u-PA and leukocyte elastase are released by neutrophils. Elastase is also able to degrade fibrin, generating fibrinopeptides differing from D-dimers, which could serve as biomarkers in abdominal aortic aneurysm (AAA) evolution 229 . MMP9 is released in association with neutrophil gelatinase-associated lipocalin (NGAL) by neutrophil activation and death 230 , and acts directly on elastin. MMPs are synthesized as inactive precursors and must be locally activated by partial plasmin proteolysis and/or by reactive oxygen species. The adventitia of AAAs is also enriched by mast cells containing tryptase and chymase in relation to adventitial neoangiogenesis 231 . Mast cells are activated by IgE binding and clustering, which triggers degranulation, releasing different vasoactive factors (serotonin, histamine, heparin, tumour necrosis factor and prostaglandins). RBC, red blood cell; TLO, tertiary lymphoid organ.
proteolytic mechanisms potentially underlie the oppo site effects that smoking and diabetes mellitus have on AAA expansion, as smoking is associated with increased proteolytic activity, whereas diabetes mellitus is associated with reduced sensitivity to proteolysis due to glycation crosslinking of the ECM macromolecules and microfibrils.
The partial disappearance of VSMCs is mainly due to the proteolytic and oxidative environment in the aor tic wall. The serine proteases plasmin and elastase can provoke VSMC detachment and death 86, 87 . In parallel, intense oxidative stress can also provoke VSMC death. For instance, ceroids (yellow brown polymers com posed of oxidized lipids and proteins) are a hallmark of oxidation, are highly toxic for VSMCs and are present in the AAA wall 87, 88 . All these proteases are regenerated and activated in the most luminal layer of the ILT and are then outwardly convected and percolate through the wall, provoking ECM degradation and VSMC loss 89 . The proteolytic injuries are partly limited by antiproteases, including tissue serpins and tissue inhibitors of MMPs (TIMPs). Thus, such plasma protease-antiprotease complexes could hypothetically serve as circulating markers of AAA progression, but the evidence for their use in clinical practice has not been substantiated. The most sensitive and accessible biomarkers for measurement would potentially be plasma MMP9 (reF.
90 ), leukocyte elastase-antitrypsin complexes, D dimers 91 and ECM degradation products.
Calcification. Calcification (precipitation of ionized calcium in soft tissue) appears very early in the evolu tion of aortic atherothrombosis and AAAs. Calcification depends on the presence of inorganic phosphates.
Sources of inorganic phosphates in arterial tissue are intracellular energy metabolism (ATP recycling), extra cellular lipoproteins, cell membrane phospholipids, free extracellular DNA (via the backbone phosphates) and the products of alkaline phosphatase. Calcification has been observed in the AAA wall, potentially associated with VSMC death and release of free DNA 92 . There is conflicting evidence regarding the role of aneurysmal aortic wall calcification in disease progression 93, 94 .
Innate and adaptive immunity AAA progression involves both innate and adaptive immunity. Under physiological conditions, the media of the infrarenal aorta is an avascular tissue and an immune privileged site devoid of capillaries. Thus, the diapedesis (the passage of blood cells through the intact walls of the capillaries) of circulating leukocytes to the media depends on neoangiogenesis 95 . By con trast, the external adventitia of the aorta is fully vas cularized, enabling leukocyte diapedesis, innate and adaptive immunity and inward sprouting of new ves sels in response to growth factors. The inner layer of the adventitia is the preferred, and commonly the only, site for the development of intense neoangiogenesis. In the AAA context, relative hypoxia and phospholipid metabolism producing eicosanoids could trigger neo angiogenesis by induction of vascular endothelial growth factor (VEGF) overexpression in macrophages and VSMCs. This neo angiogenesis includes dense arterioles, capillaries, venules and lymphatic vessels 96 . Innate immune activities involve the diapedesis of PMN leukocytes in the ILT, mainly by interaction with activated platelets, exposing P selectin, which binds to PSGL1 expressed on neutrophils and macrophages in the adventitia. PMN leukocyte activation and death result in a release of granule contents, including proteases, oxidant peptides, myeloperoxidase and pro inflammatory mediators such as IL8. The outward radial convection of degradation products and medi ators results in endocytosis, whereas phagocytosis mainly takes place in the inner adventitia, where macrophages predominate. The principal endocytic and/or phago cytic activity detected is the storage of ferric iron (the storage and recycling of the redox active ferrous iron from haem) from RBCs within CD68 + cells (CD68 is a marker of phagocytic functions but not of a specific cell lineage), including macrophages and fibroblasts. Ferric iron deposits can also be observed in periaortic lymph nodes 7 . Bacteria circulating in vessels have a high affinity for thrombi. In AAAs, the ILT fosters compartmentaliza tion of pathogens and promotes local innate immunity 97 . In response to bacterial infiltration, neutrophils are recruited to the ILT and release neutrophil extracellu lar traps (NETs); NETs are highly charged networks of chromatin (DNA and histones) able to retain proteases and oxidant molecules in the ILT milieu, potentially promoting aneurysmal growth and risk of rupture. Thus, viral and bacterial breakdown products further trigger innate and adaptive immunity, contributing to AAA pathogenesis. Bacterial infection can also cause a subtype of AAA, called mycotic AAA (box 2).
Box 2 | mycotic aaa
Mycotic abdominal aortic aneurysm (aaa) is not entirely an accurate term, as fungal infections rarely cause or contribute to aneurysms, and mycotic (or rather infectious) aneurysms are predominantly caused by bacteria. it is more common in asian populations than in western populations 215 . a mycotic aaa occurs as commonly in the thoracic as in the infrarenal aorta and is more often saccular than fusiform. The pathogenesis of mycotic aaa is not completely understood; there might be an underlying vulnerable lesion or plaque in the aortic wall that makes the wall susceptible to colonization by circulating bacteria (for example, from endocarditis or urinary tract infections 216, 217 ), which triggers aaa development. the type of bacterium differs based on geographical location, with a more diverse pattern in europe and the united states (30% Staphylococcus spp., 11% Streptococcus spp. and 7-10% Escherichia coli) than in asia (60% Salmonella spp.) [218] [219] [220] [221] [222] . in 20-30% of patients, the pathogen has not been determined 218, 219 . the patients are often elderly and have several other comorbidities, such as diabetes mellitus, renal insufficiency or Hiv infection [219] [220] [221] [222] . Patients with mycotic aaa have a high mortality, and they can develop a fistula, an erosive process between their aorta and bowel (aortoenteric fistula) that commonly causes gastrointestinal bleeding, anaemia and an extremely poor prognosis 223 . the only curative treatment for mycotic aaas is surgical, by local resection of the aneurysm, and commonly an extra-anatomical bypass. antibiotic therapy is important preoperatively and postoperatively, but there are few reports on this as a sole curative treatment 222, 224 . a 6-12-month period of antibiotic therapy is recommended in patients successfully treated with open repair surgery. in a large multicentre series, 132 patients were treated for mycotic aaa over 20 years, with 30-day and 1-year survival of 86% and 79%, respectively 225 . the increasing use of endovascular aortic repair (evar) in patients with mycotic aaa is debated and should probably be accompanied by a longer preoperative and postoperative use of antibiotics [219] [220] [221] . Adaptive immune responses to the proteolytic and/or oxidative injuries of the wall also take place in the adventitia 95 . This immune response is character ized by the development of adventitial tertiary lym phoid organs (TLOs), which are organized lymphocytic neo granulomas with a germinal centre composed of B cells and can mature the adaptive immune response towards antibody production. These germinal centres are surrounded by endothelial venules, follicular den dritic cells and T follicular helper cells, which stimulate immunoglobulin switching through a specific and com plex cytokine network 98 . This adaptive immune response depends on two main conditions: a specific inter T cell and interleukin network to organize the TLO struc ture and outwardly convected neo antigens to drive anti body maturation. Neo antigens are self molecules with oxidative or proteolytic modifications that reveal new modified epitopes that could stimulate the immune sys tem. TLOs produce polyspecific antibodies against these neo antigens (Fig. 2) . There is no direct retro diffusion of antibodies to the media or the ILT; the antibodies are released into the general circulation and reach their molecular targets from the arterial circulation.
There is evidence that complement pathways are activated in AAA 99 . In humans, molecular elements of the complement cascade predominate in the ILT 99 . Nevertheless, the exact pathophysiology of complement activation in human AAA remains to be more clearly defined. Current data support the hypothesis that the adventitial immune adaptive response in AAAs might be more an active participant than a bystander in AAA growth and rupture risk. . Inflammatory AAAs are rare and are associated with the exacerbation of the adventitial immune response, involving oedema, porosity, phagocytosis and a fibrotic healing process. The adventitial inflammatory reaction creates a close adhesion between the aortic wall and the neighbouring organs: the duodenum, small intestine, sigmoid colon, ureters and even rectum. Pathological examination of these adhesions shows dense fibrosis with an intense infiltration of lymphocytes 101 . In this context, the IgG4 immune response could play a specific part in this inflammatory form 102, 103 .
Oxidative stress
Oxidative stress is present in a tissue when the free rad ical production exceeds the capacity of the antioxidant defence. This imbalance leads to cell death as a conse quence of the production of oxidized proteins, peroxides and DNA damage programmes are also reported to be associated with a decline in the incidence of ruptured AAA in men 11, [108] [109] [110] . Only a very small fraction of patients with intact asymp tomatic AAA are diagnosed at a clinical examination because the AAA presents as a pulsatile mass or because a large AAA compresses other intra abdominal organs.
Patients with ruptured AAA who are admitted to the emergency department usually present with abdominal pain. However, the classic triad of clinical signs (abdom inal or back pain, hypotension or shock, and abdominal pulsatile mass) 111, 112 does not always lead to an accurate diagnosis of AAA, as only 25-50% of patients with ruptured AAA demonstrate all signs 111, 112 . Today, most patients admitted to the emergency room with severe abdominal pain undergo ultrasonography (Fig. 3) to con firm or exclude the existence of an AAA; if an AAA is detected, a CT angiogram is performed. The most com mon differential diagnoses include acute myocardial infarction, kidney stone, backpain and gastrointestinal diseases such as perforated ulcers.
CT increases the specificity of the diagnosis of rupture (to ~85%), evaluates morphological suitabil ity for EVAR and also improves the quality of open repair surgery.
Conventional imaging
Ultrasonography of the abdomen is generally considered the gold standard for AAA diagnosis and monitoring in asymptomatic patients, as it has a nearly 100% diag nostic accuracy 113 , and is harmless, non invasive and affordable, with portable scanners being widely availa ble. Patients with an intact large (>55 mm) AAA or those with a symptomatic or ruptured AAA, regardless of the size, usually also undergo CT imaging. CT angiograms should preferably be performed with a <0.5-1 mm slice thickness and with contrast in the arterial phase. CT is the imaging standard of reference for AAA 62 , can additionally detect possible concurrent aneurysmal disease in other vessels and enables the planning of surgical intervention. MRI cannot be performed in emergency situations but is important as an adjunct imaging method, specifically in patients with contraindications to iodinated CT contrast agents, such as renal insufficiency and allergy.
Functional imaging
Functional imaging refers to the assessment of patho physiological pathways involved in diseases; PET is the flagship method for metabolic and molecular imaging in clinical practice. A radionuclide, also known as a tracer, that often specifically tracks physiological processes or tissues is injected, and PET produces 3D images based on the tracer concentration in the tissues and organs. 18 F FDG, a glucose analogue, is one of the most widely used tracers; it enters cells and is phosphorylated to 18 FFDG6phosphate. As 18 FFDG6phosphate can neither enter the glycolytic cycle nor exit the cell, its accu mulation identifies sites of increased glycolysis, such as inflammatory foci and cancer 114 . Some models of scanner combine PET and CT within the same gantry, enabling the coregistration of PET and CT data and accurate anatomical localization of the tracer uptake (Fig. 4) .
Imaging AAA using PET is challenging, as 18 F FDG uptake in AAA is nonspecific 115 . In addition, a marked decrease in cell density in AAAs 116 and substantial background noise on PET images decrease the chance of observing 18 F FDG uptake 117, 118 . Nevertheless, sev eral studies have shown that 18 F FDG uptake in AAA is associated with inflammatory and phagocytic cell infiltrates [119] [120] [121] [122] [123] , proteolytic activity by MMPs 120,124 and cellular and molecular signalling preceding rupture 125 . The ability of iron oxide tracers to alter the MRI signal provides another option for functional imaging in AAA, as iron oxides are specifically phagocytized by the reticulo endothelial system (mainly by macro phages) 126, 127 . Diffusion weighted imaging (DWI) is a type of MRI sequence that evaluates the movement of water molecules in tissues; similarly to 18 F FDG-PET, DWI MRI is sensitive to cellular density and can, there fore, contribute to the functional assessment of AAA. The expected correlation between DWI MRI and used to evaluate periaortic neoangiogenesis as a marker of instability 129, 130 . The relationship between functional imaging find ings and patient outcomes is supported by animal mod els of AAA 131, 132 . Nevertheless, a meta analysis 133 found conflicting results when predicting AAA growth rate or rupture using functional imaging. Interestingly, 18 FFDG uptake seemed to be an indicator of AAA growth only in subgroups of patients in whom AAA growth was rapid 134 . Furthermore, in studies reporting rupture as the end point, the site of rupture almost always spatially colocalized with increased 18 F FDG uptake 119, 135 .
Computational analyses
3D anatomy provided by imaging techniques (CT, MRI and ultrasonography, in decreasing order of relevance) may offer an alternative assessment of the risk of rup ture via finite element analysis (FEA) (Fig. 5) . FEA esti mates the pressure acting on the aortic wall (that is, the wall stress) and promoting dilatation and rupture risk on the basis of computational models obtained from 3D images.
A meta analysis compiled nine studies (348 patients) that retrospectively evaluated whether FEA differenti ated between intact (or asymptomatic) and ruptured (or symptomatic) aneurysms 136 . The maximal wall stress was significantly higher in ruptured or symptomatic aneu rysms than in intact or asymptomatic aneurysms in seven of the nine studies 137, 138 . In addition, wall stress estimates better differentiate ruptured and intact AAAs than the maximal aortic diameter. There have also been prelim inary studies on the association between wall stress and AAA growth rate 139, 140 . Wall stress estimates from images can be correlated to the wall resistance obtained from in vitro biomechanical testing of aortic tissues to provide a biomechanical relative rupture risk index, which dis criminates symptomatic versus asymptomatic aneurysms better than wall stress; however, there is no prospective validation of this relative rupture risk index 141 . Despite the ongoing refinements of computational analyses, their widespread use in AAAs is limited by the availability of technical resources and concerns that the generalized assumptions on which these ana lyses are based (for example, regarding haemodynam ics and the structural properties of the AAA wall) may not apply to specific cases 142 . Thus, the role of compu tational analyses in predicting the rupture site in AAA is debatable 143 . Several investigations have reported a spatial colocalization of the maximal wall stress and the rupture site 135,141 , and areas under high wall stress exhibited histopathological features of aneurysmal wall weakening compared with areas under low wall stress on the same aneurysm 144, 145 . However, the relationship between elevated wall stress estimates and other haemo dynamic parameters and rupture is not established. Indeed, areas of high wall stress spatially colocal ize poorly with aortic wall blebs (localized bulges) 146 or inflammation, as determined by either uptake of 18 F FDG on PET imaging or iron oxide contrast agent on MRI 147,148 . Thus, inflammation and wall stress may represent different but complementary features of AAA progression.
Screening
Knowledge of the natural history of AAA has vastly improved from the large AAA screening and surveil lance trials 11, 108, 109 . Population based screening has been shown to reduce AAA related mortality in men; such screening programmes have been implemen ted nationally in the United Kingdom and Sweden, inviting all 65year old men to a one time ultrasono graphy scan 11, 17, 108, 110 . The participation rate in the United Kingdom and Sweden is 75-85%, and the prevalence of AAA in the target population was 1-2%. However, large regional variations are often found both in prevalence and participation rates 9, 11, 13, 17, 108, 110 . These variations could depend on risk factor distribution, such as smok ing habits, and differences in the development of AAA exist for different ethnic groups, as, for example, white individuals are more prone 9 .
The maximum aortic diameter at the latest control will influence the surveillance interval. Structured sur veillance protocols are commonly used at most vascular departments for patients with asymptomatic AAA and also indicate when patients should be evaluated for aor tic repair -approximately at 55 mm, see below 73 (Fig. 6 ).
The majority (70%) of men who are diagnosed with AAA in screening programmes have AAAs <45 mm in diam eter; thus, this patient group will be observed for a long time with consecutive ultrasonography examinations before treatment is considered [108] [109] [110] . As the prevalence of AAA is expected to decline, the cost-benefit balance of AAA screening in men has been re evaluated in several cost effectiveness models. If the AAA prevalence falls below 0.35-0.5% and the inciden tal detection rates increase further, the cost effectiveness will decrease, and the programmes will need to be a b 110, 149, 150 . A summary of the first 10 years of screening programmes in Sweden confirmed the bene fit of screening men in population based programmes, and this benefit is similar to that reported from previous large randomized clinical trials of AAA screening 108, 110 . The introduction of screening was associated with a reduction in AAA specific mortality in men (mean: 4.0% per year of screening; P = 0.020). After a mean of 4 years, 29% of patients with AAA had received aortic repair, with a 30day mortality of 0.9%, which is com parable to the 26% of patients who had received surgery in the MASS (Multicentre Aneurysm Screening Study) trial at 4 years follow up 108, 110 . Screening also decreases all cause mortality in screened men compared with an unscreened population 151 . In recent years, there has been some debate, opposing population based screening programmes in general. Some groups have suggested that the screening programmes diagnose men who will never be treated for their AAA, thereby over diagnosing the condition. However, the effects of the programmes on the decrease in aneurysm related mortality and also on allcause mortality are clear when popu lation based screening programmes within 7 years are analysed 11, 110, 151, 152 . The quality of life (QOL) aspects are discussed below.
There is no evidence that supports the implementa tion of population based screening in women, mainly owing to the lower prevalence and later onset of disease than in men 10, 36 . Targeted screening of patient groups with specific risk factors (for example, subaneurysmal aorta (2.5-2.9 cm in diameter), smoking or family his tory) could prove to be efficient and would also include women at risk; however, the practical implementation and cost effectiveness remain uncertain 62 .
Management
A ruptured AAA is a surgical emergency, and immediate treatment is required. Patients who present with a symp tomatic but non ruptured AAA can also require prompt treatment. Contemporary management of patients with ruptured AAAs can be performed either by EVAR or open repair surgery [153] [154] [155] .
In most modern vascular services, 75-85% of AAA repairs are performed electively for intact aneu rysms 155, 156 . Patients with an asymptomatic fusiform AAA ≥5.5 cm in diameter should be considered for elec tive repair. Of note, elective repair is also recommended for patients with a saccular AAA, which generally has a smaller diameter than fusiform AAAs, although speci fic guidelines for saccular AAAs are lacking owing to the infrequent presentation of this type of AAA 62 . Early elective repair can occasionally be considered for patients with AAAs of small diameter (≤5.5 cm) but rapid expansion rate and for young and healthy patients, particularly women, with AAAs 5.0-5.4 cm. By con trast, in patients with AAAs ≥5.5 cm but of advanced age or with substantial comorbidities and risk factors, elective repair may be delayed or inappropriate 62 . The management of AAAs has improved substan tially since the first resection was performed (Fig. 7) . In a modern vascular service, two treatment options are available for elective repair: open surgery or EVAR. Several randomized controlled trials have analysed the differences in long term outcomes between EVAR and open repair surgery (see below). Several factors, on different levels, will influence the choice between the two procedures, including reimbursement issues and factors related to the hospital, surgeon and patient. Reimbursement, mainly depending on the possibility of patients having their AAA repair tax funded or fee forservice, can often explain the major differences in the rates of EVAR and open repair surgery between countries and continents. EVAR is rarely used in most countries in Africa or Southeast Asia 9 . The pre ferred use of certain techniques by hospitals and sur geons, or the availability of access to hybrid operating suites and grafts can commonly influence regional dif ferences, even in countries with tax funded repair. The AAA morphology and the patient's ability to adhere to postoperative radiological controls after EVAR often influence choices on a local or regional level. In all surgical specialties, the introduction and widespread use of a new surgical technique will decrease the use of the surgical technique that was previously the standard of care and thereby the related skills of health care workers; this phenomenon was reported for open cholecystectomies (surgical removal of the gall bladder), which was replaced by laparoscopy in the 1990s. A similar development is also observed now, as open repair surgery is replaced by EVAR in many vascular centres worldwide. This will have clinical implications for patients who require complex open aortic procedures in the future, for example, patients who need explantation of failing EVAR grafts or experience graft infections.
The annual number of treated patients, as well as the distribution between interventions for ruptured and intact AAAs, varies between regions and coun tries, and the screening activity in the population will influence the proportion of elective repair. Intervention may be considered earlier than the protocol suggests for patients with rapidly growing abdominal aortic aneurysms (AAAs; 10 mm per year), an AAA with increased PET signals, saccular AAAs, mycotic AAAs, inflammatory AAAs or family history of AAA rupture. If the patient is not fit for surgery, the lower threshold for surgery is re-evaluated and increased (>6 cm). Follow-up for AAAs 2.5-2.9 cm in diameter is debated but can be considered in women and younger patients.
likely reflecting the fee forservice health care sys tem in the United States rather than the general gov ernmental reimbursement systems commonly used in Europe 13, 155, 157 . The mean aortic diameter in treated patients is also a marker that reflects the diversity in treatment regimens. There is a trend towards an increas ing proportion of patients with small diameter AAAs being treated in many countries, especially within fee forservice systems 155, 157, 158 .
Open repair surgery
Open repair surgery consists of the interposition of an arterial prosthesis during an open surgery. The goal is to avoid AAA rupture by replacing the aneurysmal sac with a vascular synthetic graft (Fig. 8) . Open repair surgery is usually performed with laparotomy, either through a long transperitoneal midline or a wide transverse incision. Alternatively, a left retroperitoneal approach can be used.
Open AAA repair surgery continues to be used for patients whose vascular anatomy is not suitable for EVAR (for example, with short sealing zones, multiple acces sory renal arteries or no suitable access vessels) and in regions or countries with limited resources for health care. Open repair surgery may also be offered to young and healthy individuals who are also suitable for EVAR, given that open repair surgery likely has better long term durability and a reduced need for long term surveil lance and reinterventions compared with EVAR. Open repair surgery may also be required for the treatment of complications after EVAR (for example, persistent endoleak (persistent blood flow in the aneurysmal sac after deployment of the stent graft) or aneurysmal sac growth) or for the treatment of a mycotic AAA or graft infection 62 . EVAR EVAR consists of the implantation of a bifurcated graft via the femoral and iliac arteries; the graft is anchored with stents at the normal, non aneurysmal aorta at the level of the renal and iliac arterial walls, and the aneu rysmal sac is left in situ. EVAR aims to exclude the AAA from the systemic circulation instead of replacing the damaged aorta. Several factors must be considered when assessing the feasibility of EVAR. The access ves sels should be of adequate quality to enable the introduc tion of the stent graft. Furthermore, to achieve complete sealing, healthy (non aneurysmal) proximal and distal zones are required for anchoring of the stent graft. In cases of inadequate proximal anchoring zones below the renal arteries, the suprarenal part of the aorta can be used for sealing using advanced EVAR techniques, such as fenestrated grafts (stent grafts with fenestration holes to accommodate the renal arteries and the superior mesen teric artery and coeliac trunk if needed) or the chimney technique 159 . Aortic morphology influences EVAR out comes. The performance of EVAR in patients who do not have the necessary features for this procedure is associ ated with inferior long term outcomes 160, 161 . Thus, a strict indication should be followed to achieve safe long term EVAR outcomes. In cases of questionable anatomical suitability, alternative treatment strategies (for example, open repair surgery or advanced EVAR with fenestrated or chimney grafts) should be considered 162 . In 2013, endovascular aneurysm sealing (EVAS), a new concept of endovascular AAA repair, was intro duced 163 . EVAS consists of a combination of stent grafts and polymer filled endobags that fill the aneurysmal sac to minimize the risk of endoleaks. Clinical experience with EVAS to date has shown that endobags can help to reduce type II endoleaks (back bleeding in the aneurys mal sac from lumbar arteries or other side branches of the aorta) and associated reinterventions. Nevertheless, anchoring of the endobags to the aneurysmal sac may sometimes be unstable, owing to the presence of ILTs (especially in AAAs with an increased ILT burden), and in very large AAAs, the small size of the endobags can lead to stent graft migration owing to loose fit of the endobags in the aneurysmal sac. Migration following EVAS proved to be a major issue that led to the revision of the instructions for use in 2016, excluding AAAs with a specific amount of sac ILT and also with a blood lumen diameter >70 mm (reF.
164
). Unfortunately, only mid term follow up data are available for EVAS, and before fur ther widespread use is recommended, long term data must be reported 165 . On the basis of what we learned from the long term follow up of the EVAR trials, the long term durability of a treatment modality may be more important than early technical success.
When it was first introduced, EVAR was considered only for frail patients who were not fit for open surgery. Gradually, the indications expanded to include low risk patients. Currently, EVAR is considered a safe alterna tive to open repair surgery for anatomically suitable AAAs and is actually the preferred approach in most centres 166 ( Fig. 9) . [167] [168] [169] [170] [171] [172] [173] . The DREAM (Dutch Randomized Endovascular Aneurysm Management) trial showed a benefit of EVAR compared with open repair surgery with regard to 30day mortal ity (1.2% and 4.6%, respectively; P = 0.10), complication rates (11.7% and 26.4%; P < 0.001) and length of hospi tal stay (6 days and 13 days; P < 0.001) 167 . Nevertheless, the early perioperative survival advantage of EVAR was not sustained after the first postoperative year, and EVAR was associated with higher reintervention rates than open repair surgery during 6 years of follow up (29.6% and 18.1%; P = 0.03) 168, 169 . Similarly, the UK EVAR 1 (UK Endovascular Aneurysm Repair 1) trial showed an early survival advantage for EVAR, which, however, was not sustained at the 4year follow up 170, 174 . At 15 years of follow up, EVAR was associated with lower survival than open repair surgery, mainly owing to increased second ary aneurysmal sac rupture but also increased cancer mortality in the EVAR group 173 .
Comparing open repair surgery and EVAR
There have been substantial improvements in stent graft technology that may have a positive effect on EVAR durability 171, 172, 175 . Materials have been improved (for example, grafts have lower permeability and stent designs are more flexible), and deployment mechanisms have also been revised to enable more precise proximal deployment. Consequently, the long term outcomes of EVAR with current stent graft technology may improve compared with those reported in the existing studies evalu ating EVAR with previous generation stent grafts. The more recent trials comparing open repair surgery and EVAR for ruptured AAAs show that EVAR has better patient outcomes in up to a 3year follow up, including cost effectiveness and QOL 153 . However, neurological and erectile complications can rarely be observed imme diately and/or during the follow up after EVAR and open repair surgery. The incidence of spinal cord ischaemia after EVAR or open repair surgery has been reported to be 0.21% and 0.25-0.9%, respectively 176, 177 . A meta analysis showed that the prevalence of postoperative erectile dysfunction varies from 7.4% to 79% following open repair surgery and from 4.7% to 82% following EVAR 178 .
In the long term, the higher mortality but good durability associated with open repair surgery has to be balanced against the lower early mortality but inferior durability of EVAR 179 .
Non-surgical treatment
Without elective repair, AAAs usually continue to enlarge, and increasing diameter also increases the risk of rupture. Medical treatment to prevent AAA progres sion could substantially improve the management of patients with AAA [180] [181] [182] . If the abdominal aortic aneurysm (AAA) extends above the renal arteries, suprarenal clamping may be preferred, which could yield an increased rate of renal dysfunction and perioperative morbidity. b | Once the graft is in place, the aortic wall is wrapped around the graft to protect it from exposure to intestines. Part a courtesy of P. Bonnet, University of Liège, Belgium.
Non-surgical therapy in experimental studies. The pro gression of an already developed AAA in small animal models can be suppressed by pharmacological interven tion [182] [183] [184] . Interventions to regulate pro inflammatory mediators, the renin-angiotensin system and prostaglan din metabolism have been demonstrated to be effective in reducing the progression of already developed AAAs 182 .
Interventions to inhibit inflammatory signalling path ways and treatments with immunosuppressive agents are also effective in halting AAA progression 182 . Notably, treatment with JUN N terminal kinase (JNK) inhibitor after the establishment of AAA formation resulted in a reduction of the aneurysmal diameter 185 . Abrogating ECM degradation using MMP inhibitors can also be effective in preventing AAA progression 186 .
Because of the considerable differences in the AAA pathophysiology of humans and animal models (box 1), the effectiveness of these pharmacological interventions has also been studied using cultures of human AAA explants. Indeed, interventions to regulate inflamma tory responses and treatments with MMP inhibitors are reported to be effective in ex vivo culture of human AAA tissues 182 . Treatment with HMG CoA reductase inhibi tors (statins) or angiotensin converting enzyme (ACE) inhibitors was also effective in reducing inflammatory responses in human AAA tissue culture 182 . In addition, cell therapy has also been suggested to be useful in preventing AAA progression. Local infu sion of bone marrowderived mesenchymal stem cells (BMMSCs), endothelial cells or VSMCs, as well as sys temic injection of BM MSCs, was shown to be effective in suppressing the progression of already developed AAAs in animal models [187] [188] [189] .
Pharmacotherapy in clinical trials. The βadreno receptor blocker propranolol was one of the first drugs to inhibit the development of AAAs in animal models 190 . However, in a randomized trial, it was not well tolerated by patients with AAAs and did not affect the growth rate of AAAs 182 . Chlamydia pneumoniae, unlike other bacteria, has been detected at a higher frequency in the wall of AAAs than in the normal aortic wall from cadavers 191 and is, there fore, suspected to have a pathogenic role in AAA devel opment, although this has not been formally proven 180, 181 . Randomized clinical trials of antibiotics, including doxy cycline and azithromycin, were conducted in patients with AAAs but did not clearly demonstrate an effect of antibiotics in reducing the AAA growth rate 182, 192, 193 . Doxycycline was expected to act as an MMP inhib itor 181 and was administered to a large number of patients for longer periods than the first trial 192 at the dose expected to inhibit MMPs, but doxycycline treat ment did not reduce AAA growth 58 . Recently, two ran domized trials with pemirolast, a mast cell inhibitor, and perindopril, an ACE inhibitor, have been reported, but neither drug reduced the AAA growth rate 59, 182, 183 . Several small observational studies demonstrated an association between statin administration and decreased AAA growth, although the beneficial effect of statins has not been confirmed in larger clinical trials 182, 183, 193 . Thus, there is currently no strong scientific evidence that sup ports pharmacological treatment to reduce AAA growth in humans 62, 194, 195 .
Quality of life
Both the diagnosis and treatment of AAAs have an effect on patients' QOL. Men recently diagnosed with an AAA show a temporary reduction in mental QOL during the first year, but then they tend to think pro gressively less about their condition 196 . By contrast, the effect on physical QOL seems to be more perma nent, and men diagnosed with AAAs have a consist ently lower physical QOL than men without AAAs 196 . Vascular surgeons and patients evaluate the success of AAA repair differently. Traditional end points that sur geons use to evaluate outcomes after a surgical proce dure include mortality and morbidity. Patients evaluate the success of their operation based on QOL, physical functioning and ability to be discharged from hospi tal to home and to resume their pre surgery lifestyle. Indeed, there is increasing recognition that QOL and patient satisfaction should be considered when evalu ating outcomes of a specific treatment 197 . Particularly for AAA repair, the risks of perioperative mortality and morbidity increase the relevance of evaluating QOL [198] [199] [200] [201] . Vascular surgeons should, therefore, aim to include evaluations of QOL and to improve patient satis faction rather than merely measuring adverse events as end points 202 . For both AAA surveillance and repair, the assessment of QOL and other patient focused out comes should be evaluated in the longer term. Such longer term follow up (up to 10 years) is rare and might be particularly relevant for patients entering surveillance programmes after EVAR. . Revascularization of the lower limbs can be achieved with different options: ligation of the aorta and axillobifemoral bypass; in situ use of cryopreserved aortic homografts; antibioticsoaked prosthetic grafts; and autologous reconstruction using femoral veins 254, 255 Sac expansion and secondary rupture Schanzer et al. 256 reported that the rate of AAA sac expansion after EVAR may be as high as 41% at 5 years, whereas other authors report a lower incidence Conventional treatment of para-anastomotic aneurysms includes surgical revision, especially in the case of infection; if graft infection is excluded, relining and extension of the repair with a stent graft can offer a less-invasive treatment 261 Surgery suggest the use of duplex ultrasonography as the gold standard for long term EVAR surveillance in patients without sac expansion or other complications, rather than annual CT scans. CT is more expensive, incurs radiation burden and could, in the long term, affect QOL. Doubts and fears about the durability of EVAR remain and have been exacerbated by reports about low profile devices (in which the fabric is thinner such that the device can fit in smaller delivery catheters) 203 . These fears, together with the continuing threat of reinter vention (much more common after EVAR than after open repair surgery), may affect patients' QOL as well as patient anxiety and depression (which are almost never assessed). One of the few examples of long term QOL follow up comes from the DREAM trial, which showed that although EVAR was associated with less reduction in QOL in the short term Reported QOL outcomes should be interpreted with caution, owing to the inherent subjectivity of patient reported outcomes. After open AAA repair surgery, patients are more willing to accept perioperative com plications and discomfort, whereas after EVAR, patients expect to recover quickly without major problems. Any deviation from such preoperative expectations can bias patient reported QOL outcomes 204 . However, the sur gical trend towards defining core outcome data sets mandates patient participation in defining the key out comes reported; thus, in the future, we can expect to see patient focused outcomes more widely reported.
Outlook AAA remains an important disease, as smoking remains rife in developing countries, and a growing number of elderly patients are diagnosed with AAA in developed countries. This observation depends on the ageing popu lation, with AAA becoming diagnosed at older ages, while the advent of EVAR has also extended the number of patients, even elderly ones, who are eligible for elective AAA repair.
Since 2000, there have been several developments in the management of AAA. Furthermore, a large body of research has been accumulated on the risk factors and pathophysiology of AAA and potential non surgical therapies. The effectiveness of minimally invasive EVAR for both elective and emergency cases has been substan tiated by several randomized trials and meta analyses of these trials. These same trials, together with other evidence, have also exposed some of the weaknesses of EVAR, the rather poor long term durability compared with open surgical repair, the potential need for lifelong surveillance and the limited applicability of this newer technique to women 207, 208 . Ongoing research and devel opment programmes are addressing these issues, using advances in materials science, including the avoidance of metallic components in endografts. The alternative approach of EVAS remains under evaluation, and as new data emerge, additional morphological restric tions are being placed on the use of EVAS. Controversy is widespread concerning the operative management of aneurysms that extend close to or above the renal arteries, including how endovascular techniques should be modified or adapted for these complex aneurysms. Other problems that remain to be addressed include reducing the morbidity and mortality from AAA in women and ethnic minorities. Patients diagnosed with AAAs will require continuous surveillance, commonly with ultrasonography, to determine whether it is time to consider elective repair. As small AAAs are common and readily detected by non invasive, low cost ultra sonography screening, finding therapeutic agents that will prevent further AAA growth and the need for any future operative repair remains a major goal.
Experimental animal studies have provided many new leads (potential targets for future pharmaceutical therapies), particularly in cell signalling pathways, often with very effective functional imaging modali ties and targeted treatments in these animal models. However, most of these studies were performed in small animal models, where AAA induction is rapid and not dependent on smoking, in sharp contrast to the indo lent course of small AAA in humans, where smoking remains the most important risk factor. In addition, bias might have been introduced by the lack of adequate observer blinding, insufficient number of animals in experimental groups or use of only one of the available animal models 209 . Although GWAS and other molecular studies have identified genetic variants and genetic loci associated with the development of AAA, translational research aimed at producing effective drugs to limit AAA growth is limited. New epidemiological studies have suggested other new therapeutic targets or drugs to limit the pro gression of AAAs, but none of these therapies has yet been shown to be effective in properly conducted ran domized trials 58, 59, 182, 185, 210, 211 . For AAA, the field of trans lational biology, together with other technologies, for example, nanotechnology (target drug release), remains wide open. The success of such approaches in thoracic aortic aneurysms and dissections provides insight into why genetic and basic science research on AAAs in humans must continue. For thoracic aortic aneurysms and dissections, major causal genes have been identi fied together with associated pivotal signalling pathways, which have allowed effective targeted pharmacological therapies to be developed and validated in randomized trials. Monogenic disorders are rare in AAA, perhaps emphasizing the different embryological derivation of the thoracic and abdominal aorta. However, AAAs are much more common than thoracic aortic aneurysms and dissections, and the need for further genetic and basic science research to identify pivotal cell signalling path ways and to develop other effective novel therapeutic approaches for AAA remains urgent. Pharmacological therapy for AAA should not be limited to preventing aneurysmal growth. Additional targets include prevent ing distal and proximal aneurysmal extension following surgical correction and reducing the risk of aneurysmal rupture in those with large AAAs who are not consid ered candidates for AAA repair. In summary, present day interventions to prophylactically repair AAAs still have a certain early mortality (at best 1-2%), morbid ity and consequences for long term health and health costs. In developed countries, a better knowledge of the epidemiology of AAAs in ageing populations, the AAA growth rate and the true incidence of rupture, together with a demonstration of genetic mechanisms and the elucidation of the biochemical, cellular and immuno logi cal pathways involved in genetic and environmen tal risk factors, will provide us with a comprehensive approach for better management of those with AAAs. The immuno logical pathways may have particular relevance for the AAAs of infectious aetiology, which may be most common in developing countries. Such knowledge will enable us to achieve better outcomes for AAA repair and to develop new, effective, prophylactic pharmacological therapies.
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